Tekturna Shows Non-Inferiority To Merck’s Cozaar On Left Ventricular Hypertrophy
This article was originally published in The Pink Sheet Daily
Executive Summary
Combination of both medicines, however, did not achieve a statistically significant reduction in LVH over losartan alone.
You may also be interested in...
Novartis/Speedel’s Tekturna-Diuretic Combination Clears FDA
Fixed-dose blood pressure pill will reach market in early February, Novartis tells “The Pink Sheet” DAILY.
Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension
The first-in-class drug will launch later in March.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.